Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery
- PMID: 29281027
- DOI: 10.1093/hmg/ddx438
Cas9/sgRNA selective targeting of the P23H Rhodopsin mutant allele for treating retinitis pigmentosa by intravitreal AAV9.PHP.B-based delivery
Abstract
P23H is the most common mutation in the RHODOPSIN (RHO) gene leading to a dominant form of retinitis pigmentosa (RP), a rod photoreceptor degeneration that invariably causes vision loss. Specific disruption of the disease P23H RHO mutant while preserving the wild-type (WT) functional allele would be an invaluable therapy for this disease. However, various technologies tested in the past failed to achieve effective changes and consequently therapeutic benefits. We validated a CRISPR/Cas9 strategy to specifically inactivate the P23H RHO mutant, while preserving the WT allele in vitro. We, then, translated this approach in vivo by delivering the CRISPR/Cas9 components in murine Rho+/P23H mutant retinae. Targeted retinae presented a high rate of cleavage in the P23H but not WT Rho allele. This gene manipulation was sufficient to slow photoreceptor degeneration and improve retinal functions. To improve the translational potential of our approach, we tested intravitreal delivery of this system by means of adeno-associated viruses (AAVs). To this purpose, the employment of the AAV9-PHP.B resulted the most effective in disrupting the P23H Rho mutant. Finally, this approach was translated successfully in human cells engineered with the homozygous P23H RHO gene mutation. Overall, this is a significant proof-of-concept that gene allele specific targeting by CRISPR/Cas9 technology is specific and efficient and represents an unprecedented tool for treating RP and more broadly dominant genetic human disorders affecting the eye, as well as other tissues.
Similar articles
-
Retinal degeneration in humanized mice expressing mutant rhodopsin under the control of the endogenous murine promoter.Exp Eye Res. 2022 Feb;215:108893. doi: 10.1016/j.exer.2021.108893. Epub 2021 Dec 14. Exp Eye Res. 2022. PMID: 34919893
-
Effect of AAV-Mediated Rhodopsin Gene Augmentation on Retinal Degeneration Caused by the Dominant P23H Rhodopsin Mutation in a Knock-In Murine Model.Hum Gene Ther. 2020 Jul;31(13-14):730-742. doi: 10.1089/hum.2020.008. Epub 2020 Jun 26. Hum Gene Ther. 2020. PMID: 32394751
-
In vivo Editing of the Human Mutant Rhodopsin Gene by Electroporation of Plasmid-based CRISPR/Cas9 in the Mouse Retina.Mol Ther Nucleic Acids. 2016 Nov 22;5(11):e389. doi: 10.1038/mtna.2016.92. Mol Ther Nucleic Acids. 2016. PMID: 27874856 Free PMC article.
-
Genomic form of rhodopsin DNA nanoparticles rescued autosomal dominant Retinitis pigmentosa in the P23H knock-in mouse model.Biomaterials. 2018 Mar;157:26-39. doi: 10.1016/j.biomaterials.2017.12.004. Epub 2017 Dec 5. Biomaterials. 2018. PMID: 29232624 Free PMC article.
-
Gene augmentation for adRP mutations in RHO.Cold Spring Harb Perspect Med. 2014 Jul 18;4(9):a017400. doi: 10.1101/cshperspect.a017400. Cold Spring Harb Perspect Med. 2014. PMID: 25037104 Free PMC article. Review.
Cited by
-
Losing, preserving, and restoring vision from neurodegeneration in the eye.Curr Biol. 2023 Oct 9;33(19):R1019-R1036. doi: 10.1016/j.cub.2023.08.044. Curr Biol. 2023. PMID: 37816323 Review.
-
Treatment of autosomal dominant retinitis pigmentosa caused by RHO-P23H mutation with high-fidelity Cas13X in mice.Mol Ther Nucleic Acids. 2023 Aug 7;33:750-761. doi: 10.1016/j.omtn.2023.08.002. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37621413 Free PMC article.
-
Genome editing in the treatment of ocular diseases.Exp Mol Med. 2023 Aug;55(8):1678-1690. doi: 10.1038/s12276-023-01057-2. Epub 2023 Aug 1. Exp Mol Med. 2023. PMID: 37524870 Free PMC article. Review.
-
Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa.Elife. 2023 Jun 5;12:e84065. doi: 10.7554/eLife.84065. Elife. 2023. PMID: 37272616 Free PMC article.
-
rAAV-PHP.B escapes the mouse eye and causes lethality whereas rAAV9 can transduce aniridic corneal limbal stem cells without lethality.Gene Ther. 2023 Sep;30(9):670-684. doi: 10.1038/s41434-023-00400-6. Epub 2023 Apr 19. Gene Ther. 2023. PMID: 37072572 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous